211 related articles for article (PubMed ID: 28492810)
1. Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice.
Chen B; Hu N
Braz J Med Biol Res; 2017 May; 50(6):e6141. PubMed ID: 28492810
[TBL] [Abstract][Full Text] [Related]
2. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
[TBL] [Abstract][Full Text] [Related]
3. CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors.
Kabir M; Iyer MS; Richey JM; Woolcott OO; Asare Bediako I; Wu Q; Kim SP; Stefanovski D; Kolka CM; Hsu IR; Catalano KJ; Chiu JD; Ionut V; Bergman RN
Am J Physiol Endocrinol Metab; 2015 Oct; 309(8):E747-58. PubMed ID: 26306598
[TBL] [Abstract][Full Text] [Related]
4. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
[TBL] [Abstract][Full Text] [Related]
5. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade.
Crespillo A; Suárez J; Bermúdez-Silva FJ; Rivera P; Vida M; Alonso M; Palomino A; Lucena MA; Serrano A; Pérez-Martín M; Macias M; Fernández-Llébrez P; Rodríguez de Fonseca F
Biochem J; 2011 Jan; 433(1):175-85. PubMed ID: 20955176
[TBL] [Abstract][Full Text] [Related]
6. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cannabinoid Receptor 1 Can Influence the Lipid Metabolism in Mice with Diet-Induced Obesity.
Wei LW; Yuan ZQ; Zhao MD; Gu CW; Han JH; Fu L
Biochemistry (Mosc); 2018 Oct; 83(10):1279-1287. PubMed ID: 30472964
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity.
Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT
Int J Mol Med; 2016 Mar; 37(3):743-54. PubMed ID: 26847930
[TBL] [Abstract][Full Text] [Related]
9. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.
Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J
Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
12. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.
Lim SY; Davidson SM; Yellon DM; Smith CC
Basic Res Cardiol; 2009 Nov; 104(6):781-92. PubMed ID: 19462153
[TBL] [Abstract][Full Text] [Related]
13. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
[TBL] [Abstract][Full Text] [Related]
14. CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Kim SP; Woolcott OO; Hsu IR; Stefanoski D; Harrison LN; Zheng D; Lottati M; Kolka C; Catalano KJ; Chiu JD; Kabir M; Ionut V; Bergman RN; Richey JM
Am J Physiol Endocrinol Metab; 2012 May; 302(10):E1261-8. PubMed ID: 22374758
[TBL] [Abstract][Full Text] [Related]
15. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease.
Jorgačević B; Vučević D; Vesković M; Mladenović D; Vukićević D; Vukićević RJ; Todorović V; Radosavljević T
Can J Physiol Pharmacol; 2019 Feb; 97(2):120-129. PubMed ID: 30673308
[TBL] [Abstract][Full Text] [Related]
16. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
[TBL] [Abstract][Full Text] [Related]
17. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
18. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
[TBL] [Abstract][Full Text] [Related]
19. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.
Ravinet Trillou C; Delgorge C; Menet C; Arnone M; Soubrié P
Int J Obes Relat Metab Disord; 2004 Apr; 28(4):640-8. PubMed ID: 14770190
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
